The fact that you write this: "Are you saying Advent , with all the costs and expenses and staff of a legit manufacturing facility gets the shorter end of the stick" to NWBO? demonstrates a breathtaking width and depth of ignorance about the biotech (or for that matter, any manufacturing) business. It's hard to believe that anybody can write a word about biotech without understanding the basics of the business regarding who owns the IP and therefore stands to profit, so it may be that you do understand but are expecting your readers to be completely ignorant about the biotech business.
NWBO is structured the way it is, as an almost virtual company, using many expert contractors to do a lot of the most important work in trial and RA application strategy and execution. This was to get to where they are with the lowest possible expense. In hindsight perhaps it would have been cheaper and faster to build and pay directly a bigger payroll, but that is water under the bridge and the fact is that NWBO has raised and spent a small fortune to take DcVax this far, through a ph 3 clinical trial and RA application. NWBO owns the patents and all related IP - that is where all of the value is and that is why almost all the profits of commercial sales of DcVax go to NWBO. Advent's role is only to manufacture DcVax. They did not develop it. Advent owns nothing about DcVax that they can sell to any 3rd party. There was also considerable expense in developing and validating with the RA the manufacturing setup, which Advent did, however, that was 100% paid for by NWBO which is why NWBO owns all of the manufacturing process IP that they jointly developed.
This is biotech 101, even pre-101! A contract manufacturer doesn't somehow get ownership of the IP, short of buying out the developing company. The view you wrote on this, more than anything else you have claimed, is absurdly laughable. If you believe what you wrote it's so true what I wrote yesterday half in jest, that you know nothing, nothing about the biotech business.
